Interactome screening implicates BAG6 as a suppressor of UBQLN2 misfolding in ALS/FTD

Read full text
Authors: Sang Hwa Kim, Claire E. Boos, Mark A. Scalf, Akasha K Wilkemeyer, Lloyd M. Smith, Randal S. Tibbetts
Cited by: 0
References: 70

Abstract

Ubiquilin-2 (UBQLN2) is a ubiquitin (Ub)-binding shuttle protein that is mutated in X-linked forms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). ALS/FTD-linked mutations in UBQLN2 disrupt its conformation, increasing its tendency to form cytoplasmic aggregates that may disrupt cellular regulation through loss-of-function (LOF) and gain-of-function (GOF) effects. Here, we performed quantitative mass spectrometry (MS)-based interactome analysis of wild-type (UBQLN2 WT ) and ALS-mutant UBQLN2 (UBQLN2 ALS ) proteins using inducible pluripotent stem cells (iPSCs) and induced motor neurons (iMNs). Proteins showing enhanced association with UBQLN2 ALS proteins included PEG10, a known degradation target of UBQLN2, and BAG6, a chaperone involved in the triage of mislocalized proteins (MLPs). BAG6 knockdown inhibited the solubility recovery of both UBQLN2 WT and UBQLN2 ALS proteins following heat stress (HS), suggesting it functions as a UBQLN2 holdase. In addition, knockdown of BAG6 or knockout of UBQLN2 led to PEG10 accumulation, implicating both in PEG10 turnover; however, neither BAG6 nor UBQLN2 was required for PEG10 degradation in response to HS. A highly aggregation-prone UBQLN2 4XALS mutant harboring four different ALS-associated mutations showed increased PEG10 binding and modestly delayed PEG10 turnover while PEG10 degradation was not significantly different between UBQLN2 WT and iPSCs expressing a UBQLN2 P497H clinical mutant. The combined findings implicate BAG6 as a UBQLN2 holdase and identify a suite of proteins whose altered binding may contribute to pathologic changes in UBQLN2-associated ALS/FTD.

Fields of Study & Subjects

Amyotrophic Lateral Sclerosis Research Ubiquitin and proteasome pathways Genetic Neurodegenerative Diseases

Publication details

Journal / source
Frontiers in Molecular Neuroscience
Volume
18
Pages
1720347–1720347
Publication date
5 January 2026
Language
EN